Literature DB >> 9126898

Petrous apex cholesterol granulomas: evolution and management.

M B Eisenberg1, G Haddad, O Al-Mefty.   

Abstract

Petrous apex cholesterol granulomas result from obstruction of the normal aeration of the petrous air cells and have traditionally been treated by drainage and stent placement via a transtemporal approach. The immediate results were quite satisfying, but recurrence rates as high as 60% have been reported in some series. The authors present their experience treating 14 patients with petrous apex cholesterol granulomas. An extended middle fossa approach and a petrosal approach were used for eight and two patients, respectively. All underwent complete removal of the granuloma and cyst wall followed by obliteration of the cavity with a pedicled strip of temporalis muscle. No recurrences were seen at a mean follow-up period of 3.8 years. Four patients who did not undergo surgery are being followed clinically and with serial magnetic resonance images. Additionally, the clinical and radiographic findings in this series give new insights into the origin and continued growth of these lesions and confirm what had been described previously only in experimental models. It is concluded that petrous apex cholesterol granulomas feature a continuum of both clinical and radiographic findings and radical removal via an extended middle fossa approach is advocated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126898     DOI: 10.3171/jns.1997.86.5.0822

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  20 in total

1.  Surgical approaches to the petrous apex: distances and relations with cranial morphology.

Authors:  Murilo S Meneses; Ana Lucila Moreira; Kelly C Bordignon; Ari A Pedrozo; Ricardo Ramina; Jeziel G Nikoski
Journal:  Skull Base       Date:  2004-02

2.  Clinicoradiological and surgical considerations in the treatment of cholesterol granuloma of the petrous pyramid.

Authors:  Ulrike Bockmühl; Hisham S Khalil; Wolfgang Draf
Journal:  Skull Base       Date:  2005-11

Review 3.  Cholesterol granulomas presenting as sellar masses: a similar, but clinically distinct entity from craniopharyngioma and Rathke's cleft cyst.

Authors:  Raúl A Hernández-Estrada; Varun R Kshettry; Ashley N Vogel; Mark T Curtis; James J Evans
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

4.  Hearing Improvement after Partial Labyrinthectomy: Resection of petrous apex cholesterol granuloma.

Authors:  Abdulrahman A Hagr
Journal:  Sultan Qaboos Univ Med J       Date:  2010-07-19

5.  Different patterns of orbital roof involvement by cholesterol granuloma.

Authors:  Adel H Alsuhaibani; Khalid Al-Rubaie; Hattan Al-Khiary; Jeffrey A Nerad
Journal:  Middle East Afr J Ophthalmol       Date:  2011-10

6.  Petrous apex cholesterol granuloma presenting as endolymphatic hydrops: a case report.

Authors:  Ho Chan Kim; Yun Suk An; Joong Ho Ahn
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-09-23       Impact factor: 3.372

7.  Cholesterol granuloma presenting as a mass obstructing the external ear canal.

Authors:  Vasilios Nikolaidis; Hariklia Malliari; Dimosthenis Psifidis; Spyridon Metaxas
Journal:  BMC Ear Nose Throat Disord       Date:  2010-04-05

8.  Endoscopic endonasal management of recurrent petrous apex cholesterol granuloma.

Authors:  Nancy McLaughlin; Daniel F Kelly; Daniel M Prevedello; Kiarash Shahlaie; Ricardo L Carrau; Amin B Kassam
Journal:  J Neurol Surg B Skull Base       Date:  2012-06

9.  Endoscopic Transnasal Approach for Cholesterol Granuloma of the Petrous Apex.

Authors:  Mohammad Samadian; Nader Akbari Dilmaghani; Navid Ahmady Roozbahany; Navid Farzin; Mohammad Bahadoram
Journal:  Case Rep Neurol Med       Date:  2015-07-21

10.  Tympanomastoid cholesterol granuloma: radiological and intraoperative findings of blood source connection.

Authors:  Giannicola Iannella; Alessandro Stasolla; Benedetta Pasquariello; Massimo Re; Giuseppe Magliulo
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-31       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.